Compare Nutanix Inc (NTNX) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutanix Inc vs 10X Genomics Inc — how do they compare? Nutanix Inc trades at $54 (market cap $14.90B), while 10X Genomics Inc trades at $47.2 (market cap $5.48B). The key difference: Nutanix Inc is far larger — about 2.7× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Nutanix Inc nearer its low. Which is the better fit depends on your goals.
| NTNX | TXG | |
|---|---|---|
Market Cap | $14.90B | $5.48B |
Sector | Technology | Health |
52-Week High | $81.12 | $45.80 |
52-Week Low | $34.41 | $11.34 |
Enterprise Value | $14.41B | $5.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutanix (NTNX) trades at $55.11, up slightly by 0.05% today, with a bullish technical trend and strong analyst support. The company reported consistent earnings beats in recent quarters, with Q1 2026 EPS of $0.47 exceeding expectations. Revenue growth is projected to rise from $2.54 billion in 2025 to $2.7 billion in 2026, while net income margin improves to 10.03%. Recent news highlights partnerships and NVIDIA certification for its storage solutions, reinforcing its hybrid cloud positioning.
The outlook for NTNX is positive, driven by earnings momentum and strategic initiatives in AI infrastructure. Investment opportunities include potential upside to the $57.80 consensus price target and expanding profit margins. Key risks involve competitive pressures in cloud computing and reliance on enterprise spending cycles, which could impact growth if macroeconomic conditions weaken.
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
